Hyperglycemia, a common side effect of the PI3K inhibitor Inavolycib, is directly linked to better patient outcomes. Patients with more hyperglycemia showed a stronger response (hazard ratio 0.38 vs. 0.51). This reframes a negative side effect as a potential biomarker of efficacy, urging physicians to manage it rather than discontinue treatment.
When patients progress on PI3K/AKT inhibitors like CAPF assertive, resistance is not primarily driven by new mutations within the PI3K pathway. In one trial, only 6% of patients developed such alterations. This suggests resistance mechanisms involve the activation of other signaling pathways, a key consideration for developing future combination therapies.
Despite impressive efficacy, the new PI3K/mTOR inhibitor getitalisib's weekly IV regimen presents a significant hurdle for adoption in the first-line setting. Patients would face years of frequent infusions, a stark contrast to standard oral therapies, raising major concerns about long-term patient adherence and quality of life.
High concordance exists between liquid and tissue biopsies (~89%) for PIK3CA mutations. However, since each method can uniquely identify mutations in some cases, using both liquid and tissue offers the most comprehensive detection strategy to determine patient eligibility for PI3K inhibitors and avoid false negatives.